Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Tracers in Healthy Controls and Alzheimer's Disease
NCT02187627Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO6924963, RO6931643 and [18F]RO-948 in Alzheimer's disease (AD) (3 arms), sponsored by Roche. Primary endpoints: Standard Uptake Value at Day 14, Standard Uptake Value Ratio at Day 14 and 4 more. Started Aug 2014; status: completed.
02
Drugs
RO6924963RO6931643[18F]RO-948
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02187627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187627.